SCHEDULE 13G: Alkeon Capital Management Discloses 2.7% Stake in Keros Therapeutics
Beneficial Ownership Disclosure
Alkeon Capital Management LLC and its founder, Panayotis D. Sparaggis, have disclosed a beneficial ownership of 2.7% in Keros Therapeutics, Inc. as of December 31, 2024.
Summary
- Alkeon Capital Management LLC and its founder, Panayotis D. Sparaggis, collectively referred to as the "Reporting Persons," have filed a Schedule 13G disclosing their beneficial ownership in Keros Therapeutics, Inc.
- As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 1,101,000 shares of Keros Therapeutics, Inc. Common Stock.
- This ownership represents 2.7% of the outstanding Common Stock of Keros Therapeutics, Inc., calculated based on 40,507,409 shares outstanding as of October 31, 2024, as reported in the company's Form 10-Q.
- Alkeon Capital Management LLC, a Delaware limited liability company, acts as the investment manager for the funds holding these shares.
- Panayotis D. Sparaggis is the Founder and Managing Director of Alkeon Capital Management LLC.
- The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
- This filing is Amendment No. 2 to the original Schedule 13G filed on February 13, 2023, and Amendment No. 1 filed on February 13, 2024, but is submitted as an initial Schedule 13G to comply with new EDGAR structured data requirements effective December 18, 2024.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or prospects. It is a routine regulatory filing.
Risks
- The document does not detail specific risks related to Keros Therapeutics, Inc. or its operations, as it is a beneficial ownership disclosure filing.
Future Outlook
This document does not contain any forward-looking statements or guidance from Keros Therapeutics, Inc. or the reporting entities regarding the issuer's future performance.
Industry Context
Keros Therapeutics, Inc. operates in the biotechnology sector, focusing on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders. The disclosure of a significant stake by an investment manager like Alkeon Capital Management indicates continued institutional interest in the biotech space, particularly in companies with potential for therapeutic innovation.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, which can be a factor in market perception and liquidity.
- Investment Professionals: Offers insight into the holdings of a notable investment firm, potentially influencing investment strategies or research.
Key Dates
| Date | Description |
|---|---|
| 2023-02-13 | Original Schedule 13G filed by the undersigned with the SEC. |
| 2024-02-13 | Amendment No. 1 to the Schedule 13G filed by the undersigned with the SEC. |
| 2024-10-31 | Date as of which 40,507,409 shares of Common Stock were outstanding, used for percentage calculation. |
| 2024-11-06 | Date Keros Therapeutics, Inc. filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024. |
| 2024-12-18 | Effective date for EDGAR structured data requirements applicable to Schedule 13G filings. |
| 2024-12-31 | Date of event which requires filing of this statement (beneficial ownership snapshot date). |
| 2025-02-14 | Date the current Schedule 13G filing was signed. |
Keywords
Keros Therapeutics, Alkeon Capital Management, Panayotis D. Sparaggis, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.